Anifrolumab, a relatively recent monoclonal antibody, is generating considerable excitement within the scientific community as a potential option for various autoimmune ailments. This innovative agent targets the https://mediajx.com/story28035255/anifrolumab-a-promising-approach-for-self-reactive-illnesses